Avantor Inc
For the period ended Dec 31, 2023. Filed Feb 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 14, 2024
AVTR$15.91+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Glossaryii
Glossary
| Description | |
|---|---|
| we, us, our | Avantor, Inc. and its subsidiaries |
| 2019 Plan | the Avantor, Inc. 2019 Equity Incentive Plan, a stock-based compensation plan |
| Adjusted EBITDA | our earnings or loss before interest, taxes, depreciation, amortization and certain other adjustments |
| AMEA | Asia, Middle-East and Africa |
| AOCI | accumulated other comprehensive income or loss |
| ASC | Accounting Standards Codification |
| BIS | the Bureau of Industry and Security |
| CERCLA | the Comprehensive Environmental Response Compensation and Liability Act |
| cGMP | Current Good Manufacturing Practice |
| COVID-19 | Coronavirus disease of 2019 |
| double-digit | greater than 10% |
| DDTC | Directorate of Defense Trade controls |
| DEA | Drug Enforcement Administration |
| DHHS | Department of Health and Human Service |
| EMA | European Medicines Agency |
| EPA | the U.S. Environmental Protection Agency |
| ERP | enterprise resource planning system |
| EU | European Union |
| EURIBOR | the basic rate of interest used in lending between banks on the European Union interbank market |
| FASB | the Financial Accounting Standards Board of the United States |
| FCPA | the United States Foreign Corrupt Practices Act |
| FDA | United States Food and Drug Administration |
| GAAP | United States generally accepted accounting principles |
| GDPR | the General Data Protection Regulation |
| Goldman Sachs | an investment banking firm and its affiliates |
| high single-digit | 7 - 9% |
| ICH Q7 | the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients |
ii
| Description | |
|---|---|
| IPO | initial public offering |
| ISO | International Organization for Standardization or international equivalents |
| ITAR | the International Traffic In Arms Regulations |
| LIBOR | the basic rate of interest used in lending between banks on the London interbank market |
| Long-Term | period other than Short Term |
| low single-digit | 1 - 3% |
| M&A | Mergers and Acquisitions |
| Masterflex | Masterflex LLC, a company we acquired in November 2021 |
| MCPS | 6.250% Series A Mandatory Convertible Preferred Stock |
| mid single-digit | 4 - 6% |
| NAV | Net Asset Value |
| NuSil | NuSil Acquisition Corp, NuSil Investments LLC and subsidiaries, a business organization with which we merged in 2016 |
| NYSE | the New York Stock Exchange |
| OCI | other comprehensive income |
| OEM | original engineering manufacturers |
| OFAC | the U.S. Department of The Treasury’s Office of Foreign Assets Control |
| OSHA | the U.S. Occupational Safety & Health Administration |
| Ritter | Ritter GmbH and affiliates, a company we acquired in June 2021 |
| RSU | restricted stock units represent awards that will vest annually and awards that contain performance and market conditions |
| SEC | the United States Securities and Exchange Commission |
| SG&A expenses | selling, general and administrative expenses |
| Short Term | period less than a year from the reporting date |
| SKU | stock keeping unit |
| SOFR | secured overnight financing rate |
| specialty procurement | product sales related to customer procurement services |
| VWR | VWR Corporation and its subsidiaries, a company we acquired in November 2017 |
iii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.